Resection of additional tissue around the tumor cavity significantly reduces the need to return to surgery for margin control.
The highest PET score following three cycles of induction chemotherapy was associated with poor outcomes in patients with early-stage disease.
Patients with incidental PE, including those with subsegmental involvement, had increased recurrence rates, despite treatment.
In a phase I study, trastuzumab duocarmazine demonstrated antitumor activity with manageable toxicity in HER2-low breast cancers and other solid tumors.
Outcomes were improved when daratumumab was combined with induction therapy prior to stem-cell transplant consolidation.
Outcomes were improved compared with standard chlorambucil plus obinutuzumab in previously untreated CLL patients with coexisting conditions.
Daratumumab added to lenalidomide-plus-dexamethasone improved outcomes in newly diagnosed patients.
The combination therapy provided a high remission rate in previously untreated older and high-risk patients.
An ultra-hypofractionated approach was found noninferior to conventional hypofractionation but was accompanied by more urinary-tract and bowel symptoms.
Cisplatin and S-1 remain the standard, based on phase III trial results.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.